Article PDF first page preview

First page of Early vs late switch to an intravitreal Dexamethasone implant after failed Anti-VEGF therapy for diabetic macular edema: A systematic review and meta-analysis

Introduction: Monthly anti-vascular endothelial growth factors (VEGF) are the primary line of management of diabetic macular edema (DME). However, a large number of patients do not respond to anti-VEGF and require Dexamethasone implants (DEXI) as a second line of therapy. There remains a clinical conundrum on the optimal timing of the switch to DEXI. We systematically reviewed the literature to assess outcomes after an early vs late switch to DEXI after failed anti-VEGF therapy in DME. Methods: Relevant studies were identified by searching PubMed, CENTRAL, Scopus, Web of Science, and Embase till 25th December 2024. We assessed changes in central retinal thickness (CRT), best-corrected visual acuity (BCVA), and risk of ocular hypertension between early vs late switch groups. Results: Six studies were included. Pooled analysis of all six studies showed that there was a tendency of improved CRT (MD: 19.01 95% CI: -27.29, 65.31 I2=85%) and BCVA (MD: 0.05 95% CI: -0.04, 0.14 I2=72%) with early switch as compared to late switch group but without statistical significance. Removing one outlier study showed statistically significant improvement in CRT (MD: 36.84 95% CI: 7.54, 66.14 I2=48%) and BCVA with early switch (MD: 0.09 95% CI: 0.08, 0.11 I2=0%). Subgroup analysis based on the definition of late switch indicated better outcomes with an early switch when the late switch was defined as after >6 anti-VEGF injections. No difference was noted in the risk of ocular hypertension between the two groups (OR: 0.81 95% CI: 0.38, 1.73 I2=30%). Conclusions: An early switch to DEXI may tend towards better outcomes as compared to a late switch in treatment-resistant DME patients. High heterogeneity of the meta-analysis and outlier studies are important limitations of present evidence which can only be resolved with high-quality randomized controlled trials.

Journal Section:
Ophthalmic Surgery
This content is only available via PDF.
The Author(s). Published by S. Karger AG, Basel
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License .
Attribution-NonCommercial